Searched for
FOSUN PHARMA
Gland Pharma shares tumble over 3% after Fosun Pharma likely sells 6.2% stake via block dealShares of Gland pharma fell 3.7% as Shanghai-based Fosun Pharma offloaded a 6.2% stake in a block deal managed by UBS, decreasing its holdi...
Fosun to pare stake in Gland PharmaShanghai-based Fosun Pharmaceutical Group, the promoter of Gland Pharma, plans to sell up to a 5% stake in the company through a block deal...
Fosun is said to plan block deals to pare stake in Gland PharmaThe listed arm of billionaire Guo Guangchang’s Fosun International Ltd. holds about 58% of Gland Pharma, which has a market value 303 billi...
Fosun drops plan to sell stake in Gland Pharma: ReportShares of Gland Pharma were up 0.8% at 1,360 rupees as of 9:50 a.m. IST. They have plunged 28% since November end, when Bloomberg News had ...
Gland says not heard from its promoter Fosun about the potential saleThe debt-laden Chinese conglomerate Fosun controlled by billionaire entrepreneur Guo Guangchang has been looking to sell non-core assets, t...
Fosun Said to Mull Sale of India’s $3.6 Billion Gland PharmaA sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...
Gland Pharma rallies 9% as Fosun mulls selling controlling stake in firmA sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...
Gland Pharma slides further on weak Q2, stress at FosunThe pessimistic outlook by the rating agency triggered speculation that the Chinese firm may likely sell its stake in the Indian pharma com...
Hong Kong halts Pfizer/BioNTech COVID-19 vaccines, investigates defective packagingThe government said it had received notice from Fosun Pharma Industrial (Hong Kong), the distributor of the Pfizer/BioNTech vaccine in the ...
Gland Pharma gets Sebi's go-ahead to float IPOThe company filed draft papers in July and obtained Sebi's observation on October 19 to float an IPO, an update with the capital markets sh...
China’s Fosun plans D-Street debut for Gland PharmaThe Hyderabad-based Gland Pharma has filed a draft red herring prospectus with capital market regulator Securities and Exchange Board of In...
74% Chinese-owned Hyderabad pharma firm files for IPOThe fresh issue and the offer for sale together is expected to take the IPO size to around Rs 3,000 crore.
Chinese firm-backed Gland Pharma files for IPO; may raise up to Rs 6,000 croreThe company may raise up to $800 million or Rs 6,000 crore, a source with the knowledge of the matter said.
Gland Pharma to leverage Fosun’s strengths for growthBiologics and biosimilar drugs are emerging hotspots, and Gland is arming itself to take a leap in this segment, which is estimated to be t...
Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 billionFosun Pharma and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added.
Fosun Group injects new life into Gland Pharma dealLast year, the government relaxed the foreign investment rules, allowing global companies to acquire up to 74 per cent in local drug makers...
Gland Pharma's deal with Fosun will open up new markets: Ravi Penmetsa, MD, Gland PharmaThe deal with Fosun is also an example of the excellence of India’s manufacturing capabilities. It goes with the essence of the Make in Ind...
Fosun agrees to buy KKR-backed Gland Pharma for $1.4 billion: SourceThe deal would be the first major move by the Fosun group since Guo Guangchang, founder of flagship holding firm Fosun International Ltd an...
China's Fosun to buy KKR backed Gland Pharma for $1.4 billionFosun has agreed to acquire 96 percent stake, which includes shares held by founders of Gland Pharma Ravi Penmetsa and family and private e...
Fosun leads the race to buy Gland Pharma with $1.27 billion bidComing from behind in a closely fought race that saw US giant Baxter and private equity fund Advent make firm offers early May, Hong Kong-l...